Artículos de revistas
Prophylactic Hpv Vaccines [vacinas Profiláticas Para O Hpv]
Registro en:
Revista Brasileira De Ginecologia E Obstetricia. , v. 29, n. 6, p. 281 - 284, 2007.
1007203
10.1590/S0100-72032007000600001
2-s2.0-37349037558
Autor
Derchain S.F.M.
Sarian L.O.Z.
Institución
Resumen
[No abstract available] 29 6 281 284 Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24 Suppl 3:S1-S10Lazcano-Ponce, E., Alonso, P., Ruiz-Moreno, J.A., Hernandez-Avila, M., Recommendations for cervical cancer screening programs in developing countries. The need for equity and technological development (2003) Salud Publica Mex, 45 (SUPPL. 3), pp. S449-S462 Lowy, D.R., Schiller, J.T., Prophylactic human papillomavirus vaccines (2006) J Clin Invest, 116 (5), pp. 1167-1173 Tewari, K.S., DiSaia, P.J., Primary prevention of uterine cervix cancer: Focus on vaccine history and current strategy (2002) Obstet Gynecol Clin North Am, 29 (4), pp. 843-868 Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271-8Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine. 2006;24(27-28):5571-83Harro, C.D., Pang, Y.Y., Roden, R.B., Hildesheim, A., Wang, Z., Reynolds, M.J., Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine (2001) J Natl Cancer Inst, 93 (4), pp. 284-292 Koutsky, L.A., Ault, K.A., Wheeler, C.M., Brown, D.R., Barr, E., Alvarez, F.B., A controlled trial of a human papillomavirus type 16 vaccine (2002) N Engl J Med, 347 (21), pp. 1645-1651 Harper, D.M., Franco, E.L., Wheeler, C., Ferris, D.G., Jenkins, D., Schuind, A., Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial (2004) Lancet, 364 (9447), pp. 1757-1765 Harper, D.M., Franco, E.L., Wheeler, C.M., Moscicki, A.B., Romanowski, B., Roteli-Martins, C.M., Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial (2006) Lancet, 367 (9518), pp. 1247-1255 Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007;369(9574):1693-702Ault, K.A., Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: A combined analysis of four randomised clinical trials (2007) Lancet, 369 (9576), pp. 1861-1868 Schiller JT, Nardelli-Haefliger D. Chapter 17: second generation HPV vaccines to prevent cervical cancer. Vaccine. 2006;24 Suppl 3:S147-53Franco EL, Cuzick J, Hildesheim A, de Sanjose S. Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine. 2006;24 Suppl 3:S171-7Zimmerman, R.K., Ethical analysis of HPV vaccine policy options (2006) Vaccine, 24 (22), pp. 4812-4820 Goldie SJ, Kim JJ, Myers E. Chapter 19: cost-effectiveness of cervical cancer screening. Vaccine. 2006;24 Suppl 3:S164-70Goldie, S.J., Grima, D., Kohli, M., Wright, T.C., Weinstein, M., Franco, E., A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine (2003) Int J Cancer, 106 (6), pp. 896-904